Back to Agenda
Session 8: Wrap-up Session: Continuous Collaboration for a Continuous Development
Session Chair(s)
Ania Mitan
Senior Vice President & Managing Director, EMEA and India
DIA, Switzerland
Join us for this summary session where we will discuss the main take aways of the Workshop and will explore practical solutions to the key questions associated with bringing cell and gene therapies to the market:
- Who are the players and what is the importance of early collaboration between them all?
- What are the key elements of a successful cell and gene therapy’s introduction to the market?
- What are practical and legislative barriers to the introduction/launch of those therapies?
- What is the readiness of key players for the arrival of cell and gene therapies? Patients, regulators, clinicians, HTA agencies, policymakers, payers and industry?
- How to limit access delays of these therapies to patients?
- How can we all keep learning about the newest developments, share successes and advance using our collective intelligence?
Speaker(s)
Panel discussion with Q&A
Alexander Natz, JD
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Secretary General
Contributing Panelist
Keith Wonnacott, PhD
Lexeo Therapeutics, United States
Vice President, Regulatory Affairs
Contributing Panelist
Maren von Fritschen, PharmD
Moderna, Netherlands
Head EU Regulatory Policy
Contributing Panelist
Martin Telko, PhD, MS
Novartis, Switzerland
Global Public Affairs Director for Biomedical Innovation
Contributing Panelist
Paolo Morgese, MSc
Alliance for Regenerative Medicine (ARM), Belgium
Head of Public Affairs
Contributing Panelist
Sam Ringle, PhD
CSL Behring Innovation Gmbh, Germany
EU Regulatory Affairs Manager
Contributing Panelist
Violeta Georgieva, LLM
EuropaBio, Belgium
Legal Affairs and Healthcare Manager
Have an account?